C. perfringens alpha toxoid vaccine
AssigneeIntervert Inc.
InventorsHuchappa Jayappa, Kevin O'Connell
Life of this patent
Estimating the term…
Abstract
The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes methods of making these vaccines.
Claims26
A vaccine comprising an antigen selected from the group consisting of a C. perfringens alpha toxoid, an antigenic fragment of a C. perfringens alpha toxoid, an inactive antigenic fragment of a C. perfringens alpha toxin, and any combination thereof;
- wherein one to two doses of 0.25-0.6 mL per dose of the vaccine is sufficient to induce at least four antitoxin units (A.U.) of anti-alpha toxin antibody per mL of antisera of a chicken vaccinated with the vaccine.
A vaccine consisting essentially of an antigen selected from the group consisting of a single i C. perfringens Type alpha toxoid, an antigenic fragment of the alpha toxoid, an inactive antigenic fragment of a single C. perfringens Type alpha toxin, and any combination thereof;
- wherein the single C. perfringens Type alpha toxoid and the inactive antigenic fragment of the single C. perfringens Type alpha toxin are the same Type;
- and
- wherein one to two doses of 0.25-0.6 mL per dose of the vaccine is sufficient to induce at least four antitoxin units (A.U.) of anti-alpha toxin antibody per mL of antisera of a chicken vaccinated with the vaccine.
A method of making a C. perfringens alpha toxoid vaccine comprising:
- (a) growing a C. perfringens cell in a culture medium to produce a quantity of cultured cells;
- wherein said quantity of cultured cells secrete a C. perfringens alpha toxin into the cell medium;
- (b) inactivating the secreted alpha toxin to produce a C. perfringens alpha toxoid;
- (c) removing a majority of the quantity of cultured cells from the culture medium to form a C. perfringens alpha toxoid supernatent;
- and
- (d) adjusting the concentration of the C. perfringens alpha toxoid supernatant so that it is sufficient to induce at least four antitoxin units (A.U.) of anti-alpha toxin antibody per mL of antisera of an avian that has been vaccinated with either one or two doses of 0.25-0.6 mL per dose of said vaccine.
Dependencies are inferred from the claim text.